1179344-30-9

Basic information

• Product Name: 1,6-diethyl-N-{[6-fluoro-3'-(1-piperazinylmethyl)-3-biphenylyl]methyl}-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
• Synonyms: 1,6-diethyl-N-{[6-fluoro-3'-(1-piperazinylmethyl)-3-biphenylyl]methyl}-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
• CAS NO: 1179344-30-9
• Molecular Weight: 599.752
• Mol File: 1179344-30-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1,6-diethyl-N-{[6-fluoro-3'-(1-piperazinylmethyl)-3-biphenylyl]methyl}-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 1,6-diethyl-N-{[6-fluoro-3'-(1-piperazinylmethyl)-3-biphenylyl]methyl}-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide(1179344-30-9)
• EPA Substance Registry System: 1,6-diethyl-N-{[6-fluoro-3'-(1-piperazinylmethyl)-3-biphenylyl]methyl}-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide(1179344-30-9)

Safety Data

• Hazardous Substances Data: 1179344-30-9(Hazardous Substances Data)

Upstream product

• 87199-16-4 3-Formylphenylboronic acid 
• 865314-28-9 (3-((4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)phenyl)boronic acid 
• 865713-80-0 6-ethyl-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 
• 1177558-87-0 1,1-dimethylethyl 4-{[5'-(aminomethyl)-2'-fluoro-3-biphenylyl]methyl}-1-piperazinecarboxylate 
• 865713-74-2 ethyl 6-ethyl-1-ethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 
• 865713-68-4 ethyl-4-chloro-6-ethyl-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 
• 865713-63-9 diethyl 2-(1-chloropropylidene)malonate 
• 21633-77-2 diethyl 2-propionylmalonate 

Relevant articles and documents

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.